Form 4: OnKure CEO Sells Shares for Tax Obligations

OnKure Therapeutics' President and CEO, Nicholas A. Saccomano, sold 86 shares of Class A Common Stock to cover tax withholding obligations related to RSU vesting.

Summary

• Nicholas A. Saccomano, President and CEO of OnKure Therapeutics, Inc., sold 86 shares of Class A Common Stock.
• The transaction occurred on March 23, 2026, at a weighted average price of $4.1565 per share.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) under the company's 2023 RSU Equity Incentive Plan.
• Following the transaction, Saccomano beneficially owns 7,333 shares, including certain RSUs.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale is a routine administrative action to cover tax liabilities associated with RSU vesting and does not reflect a change in the insider's investment sentiment or the company's operational performance.

Future Outlook

N/A. This filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that insider sales to cover tax obligations upon RSU vesting are a common and routine occurrence, not typically indicative of a change in management's outlook on the company's prospects. This transaction is specific to the individual's compensation structure rather than a broader industry trend.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, small-scale transaction for tax purposes, not a discretionary sale indicating lack of confidence.

Key Dates

Keywords

OnKure Therapeutics, OKUR, Nicholas A. Saccomano, Insider Trading, Form 4, Stock Sale, RSU Vesting, Tax Withholding